Kurser indlæses...
Prognose
| Køb |
2 |
| Behold |
0 |
| Sælg |
0 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
InMed Pharmaceuticals meets NASDAQ minimum bid-price requirement again
NASDAQ said InMed Pharmaceuticals has met the listing requirement after the closing price of its common stock was at or above $1.00 for ten consecutive trading days from May 19 through last Monday. The exchange has closed the matter; the stock currently trades at $1.56 and, despite a 50% year-to-date increase, remains well below the 52-week high of $5.50. InMed has a market capitalization of $6.96 million and is developing small-molecule drug candidates targeting CB1/CB2 receptors with programs for Alzheimer’s, eye diseases and dermatology. » Mere på de.investing.com
InMed Pharmaceuticals files prospectus supplement for at-the-market offering
InMed Pharmaceuticals has filed a prospectus supplement and the related prospectus with the U.S. securities regulator SEC for the sale of common shares under an existing at-the-market agreement with H.C. Wainwright & Co. The filing relies on the S-3 shelf registration that the SEC declared effective on March 30, 2026. The supplement includes a legal opinion from Norton Rose Fulbright Canada LLP on the validity of the offered securities. » Mere på de.investing.com
InMed Pharmaceuticals faces delisting after falling below Nasdaq minimum bid price
InMed Pharmaceuticals received a notice from Nasdaq because the stock’s closing price was below $1.00 for 30 consecutive trading days between Feb. 11 and Mar. 26, 2026. The shares currently trade at $0.66 with a market capitalization of $2.59 million; InMed has 180 calendar days to cure the deficiency by achieving a closing price of at least $1.00 for ten consecutive trading days. If the company does not comply, a one-time extension is possible; otherwise delisting is threatened, with a possible appeal to the Nasdaq Hearings Panel. InMed is evaluating options such as a reverse stock split and will monitor the share price. » Mere på de.investing.com
InMed Pharmaceuticals reports quarterly loss of $0.43 per share and moderate revenue increase
InMed Pharmaceuticals released results for the quarter ended June 30, 2025: loss per share was $0.43 compared with -$3.80 in the year-ago quarter. Quarterly revenue was $1.3 million (+1.56% year on year). For the full year, loss per share narrowed to $8.36 (prior year -$20.20) on revenue of $4.94 million (+7.39% year on year). » Mere på finanzen.net
InMed Pharmaceuticals sets date and record date for 2025 annual general meeting
InMed Pharmaceuticals announced the date, record date and organizational details for its 2025 annual general meeting and filed the information on SEDAR and in a Form 8‑K with the SEC. The company gave no information on agenda items or proposals. It is registered in British Columbia, headquartered in Vancouver; its common shares trade on NASDAQ under the ticker INM; market capitalization is about 4.31 million USD and the stock is down more than 52% year-to-date. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 0 | 100,00 % |
| Bruttofortjeneste | -195,14 t | 156,80 % |
| Nettoresultat | -2,06 mio. | 39,83 % |
| EBITDA | -1,58 mio. | 18,09 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 7,77 mio. € |
Antal aktier | 549,37 t |
Højeste/laveste i 52 uger | 21,19 € - 5,23 € |
| Udbytte | Nej |
Beta | 0,99 |
P/E (PE Ratio) | -0,60 |
PEG (PEG Ratio) | -0,01 |
K/I (PB Ratio) | -8,48 |
P/S (PS Ratio) | 0,00 |
Virksomhedsprofil
InMed Pharmaceuticals Inc., et farmaceutisk selskab i klinisk fase, forsker i og udvikler cannabinoidbaserede behandlinger. Selskabets vigtigste produkt er INM-755, en topisk creme med cannabinol, som er i en anden fase I-klinisk afprøvning til behandling af epidermolysis bullosa. Selskabet er også involveret i udviklingen af INM-088, som er i prækliniske undersøgelser til behandling af glaukom, og INM-405 til behandling af smerte. Desuden udvikler selskabet cannabinoidbaserede behandlinger til forskellige sygdomme, herunder dermatologiske og okulære sygdomme. Yderligere arbejder selskabet med IND-egnede farmakologiske og prækliniske toksikologiske undersøgelser samt IntegraSyn, en integreret biosyntesebaseret produktionsmetode til syntese af cannabinoider i farmaceutisk kvalitet. Selskabet har en forskningssamarbejdsaftale med BayMedica Inc. om fremstilling og test af nye cannabinoidterapeutika. Selskabet var tidligere kendt som Cannabis Technologies Inc. og ændrede navn til InMed Pharmaceuticals Inc. i oktober 2014. InMed Pharmaceuticals Inc. blev stiftet i 1981 og har hovedkontor i Vancouver, Canada.
| Navn | InMed Pharmaceuticals |
| CEO | Eric A. Adams Chem. |
| Hjemsted | Vancouver,
bc Canada |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 05.05.2014 |
| Medarbejdere | 6 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | INM |
Frankfurt | MWG.F |